Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Susanne Saußele, Markus Pfirrmann et al.|Leukemia|2017Cited by 339
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVLida Kalmanti, Susanne Saußele, Michael Lauseker et al.|Leukemia|2015Cited by 274